BioPharmSignal logoBioPharmSignal

Biotech News

ProKidney to Present at the 44th Annual J.P. Morgan Healthcare Conference

ProKidney (PROK)ProKidneyConference / presentation

WINSTON-SALEM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that ProKidney’s CEO, Bruce Culleton, M.D., will present at the 44 th

Related news

PROKProKidney2025-08-27 11:30 EST

ProKidney to Participate in Two Upcoming Conferences: the Citi Biopharma Back to School Conference and the Morgan Stanley Global Healthcare Conference

PROKProKidney2025-10-29 11:30 EST

ProKidney to Participate in Two Upcoming Conferences: Guggenheim Healthcare Innovation Conference and the Jefferies Global Healthcare Conference

View all latest news

ProKidney

Regenerative Kidney Medicine ProKidney develops cell therapies intended to preserve kidney function and delay progression to kidney failure. Its work focuses on patients with advanced chronic kidney disease and type 2 diabetes who face a high risk of dialysis or transplantation. Rilparencel Rilparencel, also known as REACT, is a...

Recent company news

PROKProKidney2026-08-10 20:05 EST

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

PROKProKidney2026-06-02 12:00 EST

ProKidney Appoints Kenneth Locke as Chief Technical Officer

PROKProKidney2026-05-15 15:45 EST

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

PROKProKidney2026-03-25 20:01 EST

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

PROKProKidney2026-03-18 20:00 EST

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

Stock data

Close
1.61 USD
Market cap
389.88M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States